Preventing Rash and Diarrhea with Capivasertib for Breast Cancer
Treatments studied
Part of Skin clinical trials.
This trial tests whether giving a combination of the drugs capivasertib and fulvestrant, along with medicines to prevent rash and diarrhea, can help treat hormone receptor-positive breast cancer that has a PIK3CA, AKT1, or PTEN change. It's for people whose cancer has spread or is locally advanced and can't be removed with surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older and have breast cancer that has spread (metastatic) or is locally advanced and can't be removed with surgery.
- Your cancer must have a specific change (mutation) in the PIK3CA, AKT1, or PTEN genes.
- You need to be in fairly good health: able to do light daily activities, have adequate blood counts, and normal liver and kidney function.
- If you are a premenopausal woman, you must be willing to take a medication (LHRH agonist) to temporarily stop your ovaries from working.
- You cannot have had prior treatment with an AKT or PI3K inhibitor like capivasertib or alpelisib.
- If you have diabetes, it must be well-controlled (HbA1c below 8%) and you cannot require insulin.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral drug called capivasertib combined with standard hormone therapy for people with advanced breast cancer that is HR-positive and HER2-negative. It is for those whose cancer has progressed on previous hormone therapy and who have a specific gene change (PIK3CA, AKT1, or PTEN).
This trial tests adding capivasertib to fulvestrant for women with a certain type of breast cancer (invasive lobular carcinoma) that is hormone-receptor positive and has a high risk of coming back. The treatment is given before surgery to see if it works better than fulvestrant alone.
This trial tests two different combinations of medicines for people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has a specific gene change called PIK3CA. The goal is to see which combination is better at slowing down the cancer.
This trial tests a new combination of drugs (AMXT 1501, DFMO, and standard therapies) for people with advanced solid tumors, specifically breast cancer (ER+ HER2-) or melanoma that has progressed after other treatments. The goal is to see if this combination can help shrink tumors or slow their growth.
This study tests how well and how safely different combinations of cancer drugs work for people with metastatic or inoperable locally advanced breast cancer. It may help by finding a better treatment option and collecting information to guide future care.
This trial tests whether combining immunotherapy, hormone therapy, and an AKT-blocking drug can control ER-positive advanced breast cancer in women whose cancer is resistant to hormone treatment. It may help shrink tumors and slow disease by targeting several pathways at once.
Hear when a new Metastatic HR+/HER2- Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.